Q-omics provides the consensus-scored ZFY-AS1 profile across patient tissues and cancer cell-line models. ZFY-AS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ZFY-AS1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ZFY-AS1 RNA expression shows 6,242 significant pathway-activity associations, with the highest sampling consensus in PRAD. Together, these results highlight THCA, KIRP, and PRAD as cancer lineages where ZFY-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFY-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFY-AS1 survival associations across molecular data types. ZFY-AS1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFY-AS1 RNA expression–survival associations across cancer types. High ZFY-AS1 expression shows unfavorable associations in THCA and CESC, but favorable associations in BLCA, UVM, HNSC and KIRC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ZFY-AS1 RNA expression.
This table summarizes ZFY-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZFY-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFY-AS1 shows lower tumor expression in KIRP, KICH, HNSC, THCA, READ and LUSC. The KIRP box plot shows higher ZFY-AS1 RNA expression in normal versus tumor tissue (log2 FC = −2.567, t-test p < 0.001).
This table shows molecular features associated with ZFY-AS1 in patient tissues and cancer cell lines. In patient samples, ZFY-AS1 shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set.
